Subsense, a Palo Alto, CA-based developer of non-surgical invasive, nanoparticle-based brain-computer interfaces (BCIs), added $10m in funding. 

The investment, which brought total funding to $27m, came from Golden Falcon Capital. 

The company intends to use the funds to accelerate research and development in nanoparticle sensing, in vivo biosafety programs, next-generation nanoparticle design, and hardware miniaturization.

Led by Tetiana Aleksandrova, Co-founder and CEO, Subsense is a neurotechnology company developing a non-surgical, nanoparticle-based bidirectional brain-computer interface. The bidirectional BCI platform is designed to record and modulate brain activity without surgical implants. Its technology pairs engineered nanoparticles, administered nasally to cross the blood-brain barrier, with proprietary hardware and signal-processing software.

Together, these systems aim to achieve higher temporal and spatial resolution of reading and stimulation than current solutions, while also avoiding the risks and costs associated with surgically invasive electrodes or “brain chips.”

Subsense recently opened a laboratory and engineering facility in Palo Alto, California, in addition to its research collaborations across North America and Europe. Its technology portfolio spans nanoparticle chemistry, magnetic signal transduction, and proprietary neural decoding algorithms aimed at safe, reversible, and high-fidelity brain data capture. 

source[FinSMEs]